Literature DB >> 9182787

Long-term survival in typical thanatophoric dysplasia type 1.

K M Baker1, D S Olson, C O Harding, R M Pauli.   

Abstract

Thanatophoric dysplasia (TD), a severe skeletal dysplasia, is virtually always lethal neonatally, although a few previous reports have documented survival up to 4.75 years. We present a patient with survival beyond age 9 years and summarize his growth, development and medical history. The common Arg248Cys mutation in the extracellular region of fibroblast growth factor receptor 3 (FGFR3) was identified, eliminating the possibility that his long-term survival is attributable to an atypical mutation. This patient (and at least one other TD long-term survivor) have a rare skin disorder, acanthosis nigricans, which also occurs in Crouzon syndrome when caused by a FGFR3 mutation. Therefore, any molecular model of the origin of acanthosis nigricans secondary to FGFR3 mutations must account for the association of diverse mutations and these cutaneous effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182787

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  Thanatophoric Skeletal Dysplasia: A Case Report.

Authors:  Firoz Anjum; Sunil Kumar Daha; Ganesh Shah
Journal:  JNMA J Nepal Med Assoc       Date:  2020-03       Impact factor: 0.406

2.  Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.

Authors:  G A Bellus; E B Spector; P W Speiser; C A Weaver; A T Garber; C R Bryke; J Israel; S S Rosengren; M K Webster; D J Donoghue; C A Francomano
Journal:  Am J Hum Genet       Date:  2000-10-27       Impact factor: 11.025

3.  FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met.

Authors:  Shannon G Farmakis; Marwan Shinawi; Michelle Miller-Thomas; Alireza Radmanesh; Thomas E Herman
Journal:  Skeletal Radiol       Date:  2014-08-15       Impact factor: 2.199

4.  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.

Authors:  P L Tavormina; G A Bellus; M K Webster; M J Bamshad; A E Fraley; I McIntosh; J Szabo; W Jiang; E W Jabs; W R Wilcox; J J Wasmuth; D J Donoghue; L M Thompson; C A Francomano
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  Thanatophoric dysplasia: a case report.

Authors:  Olusoji Edward Jagun; Mojisola Adejoke Olusola-Bello; Abiodun Folashade Adekanmbi; Omodele Oluyemisi Jagun; Tolani Oduwole
Journal:  Pan Afr Med J       Date:  2020-11-05

6.  Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.

Authors:  Christian Hafner; Johanna M M van Oers; Thomas Vogt; Michael Landthaler; Robert Stoehr; Hagen Blaszyk; Ferdinand Hofstaedter; Ellen C Zwarthoff; Arndt Hartmann
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

7.  Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood.

Authors:  Hwa Young Kim; Jung Min Ko
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-06-30

Review 8.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

9.  A case of thanatophoric dysplasia type I with an R248C mutation in the FGFR3 gene.

Authors:  Eun Jung Noe; Han Wook Yoo; Kwang Nam Kim; So Yeon Lee
Journal:  Korean J Pediatr       Date:  2010-12-31

10.  Should We Stop Calling Thanatophoric Dysplasia a Lethal Condition? A Case Report of a Long-Term Survivor.

Authors:  Ricki S Carroll; Angela L Duker; Andrea J Schelhaas; Mary Ellen Little; Elissa G Miller; Michael B Bober
Journal:  Palliat Med Rep       Date:  2020-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.